{
  "PMC": "5921855",
  "DOI": "10.1111/j.1349-7006.1998.tb03289.x",
  "PMID": "9685852",
  "PMCID": "PMC5921855",
  "title": "Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats.",
  "year": 1998,
  "source_url": "https://europepmc.org/article/PMC/PMC5921855",
  "source": "MED",
  "abstract_text": "We investigated the modifying effects of nabumetone, a relatively selective cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea(MNU)-induced mammary carcinogenesis in female Sprague-Dawley rats. A total of 124 rats, 6 weeks old, were divided into 6 groups. At 50 days of age, groups 1, 2, and 3 were treated with MNU (50 mg/kg body weight) by subcutaneous injection. From the age of 8 weeks, groups 2 and 4 were given 0.03% nabumetone in the diet and groups 3 and 5 were given 0.03% esculetin in the diet. All rats were necropsied at the termination (25 weeks after the start of experiment). The incidence and multiplicity of neoplasms in group 2 were significantly smaller than those in group 1 (P < 0.005 and P < 0.001, respectively). The incidence of neoplasms in group 3 was also significantly smaller than that in group 1 (P < 0.05). These results indicate that the intake of nabumetone or esculetin during the time corresponding to the post initiation phase has a chemopreventive effect on MNU-induced mammary carcinogenesis in rats.",
  "full_text": "Jpn J Cancer Res Jpn. J. Cancer Res 10.1111/(ISSN)1349-7006a CAS Japanese Journal of Cancer Research : Gann 0910-5050 1876-4673 Blackwell Publishing Ltd Oxford, UK 5921855 9685852 10.1111/j.1349-7006.1998.tb03289.x CAE496 Article Inhibitory Effects of Nabumetone, a Cyclooxygenase‐2 Inhibitor, and Esculetin, a Lipoxygenase Inhibitor, on N ‐Methyl‐ N ‐nitrosourea‐induced Mammary Carcinogenesis in Rats Matsunaga Kengo 1 Yoshimi Naoki 1 Yamada Yasuhiro 1 Shimizu Masahito 1 2 Kawabata Kunihiro 1 Ozawa Yuki 1 Hara Akira 1 Mori Hideki 1 1 First Department of Pathology 2 First Department of Internal Medicine, Gifu University School of Medicine, 40 Tsukasa‐machi, Gifu 500‐8705 * 3 To whom correspondence should be addressed. 5 1998 89 5 10.1111/cas.1998.89.issue-5 496 501 (Received January 26, 1998/Revised March 9, 1998/Accepted March 12, 1998) We investigated the modifying effects of nabumetone, a relatively selective cyclooxygenase‐2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N ‐methyl‐ N ‐nitrosourea(MNU)‐induced mammary carcinogenesis in female Sprague‐Dawley rats. A total of 124 rats, 6 weeks old, were divided into 6 groups. At 50 days of age, groups 1, 2, and 3 were treated with MNU (50 mg/kg body weight) by subcutaneous injection. From the age of 8 weeks, groups 2 and 4 were given 0.03% nabumetone in the diet and groups 3 and 5 were given 0.03% esculetin in the diet. All rats were necropsied at the termination (25 weeks after the start of experiment). The incidence and multiplicity of neoplasms in group 2 were significantly smaller than those in group 1 ( P <0.005 and P <0.001, respectively). The incidence of neoplasms in group 3 was also significantly smaller than that in group 1 ( P <0.05). These results indicate that the intake of nabumetone or esculetin during the time corresponding to the post initiation phase has a chemopreventive effect on MNU‐induced mammary carcinogenesis in rats. Key words: Cyclooxygenase‐2 Lipoxygenase Rat mammary carcinogenesis Chemoprevention source-schema-version-number 2.0 cover-date May 1998 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015 REFERENCES 1 ) Bennett , A. , Charlier , E. M. , McDonald , A. M. , Simpson , J. S. , Stamford , I. F. and Zebro , T. Prostaglandins and breast cancer . Lancet , ii , 624 – 626 ( 1977 ). 2 ) Bennett , A. The production of prostanoids in human cancers, and their implications for tumor progression . Prog. Lipid Res. , 25 , 539 – 542 ( 1986 ). 3321094 3 ) Jung , T. T. K. , Berlinger , N. T. and Juhn , S. K. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study . Laryngoscope , 95 , 307 – 312 ( 1985 ). 3919231 4 ) Bennett , A. , Carroll , M. A. , Stamford , I. F. , Whimster , W. F. and Williams , F. Prostaglandins and human lung carcinomas . Br. J. Cancer , 46 , 888 – 893 ( 1982 ). 6295425 5 ) Bennett , A. , Civier , A. , Hensby , C. N. , Melhuish , P. B. and Stamford , I. F. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues . Gut , 28 , 315 – 318 ( 1987 ). 3106172 6 ) Rigas , B. , Goldman , I. S. and Levine , L. Altered eicosanoid levels in human colon cancer . J. Lab. Clin. Med. , 122 , 518 – 523 ( 1993 ). 8228569 7 ) Mclemore , T. L. , Hubbard , W. C. , Litterst , C. L. , Liu , M. C. , Miller , S. , McMahon , N. A. , Eggleston , J. C. and Boyd , M. R. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients . Cancer Res. , 48 , 3140 – 3147 ( 1988 ). 3130187 8 ) Reddy , B. , Rao , C. , Rivenson , A. and Kelloff , G. Inhibitory effect of aspirin on azoxymethane‐induced colon carcinogenesis in F344 rats . Carcinogenesis , 14 , 1493 – 1497 ( 1993 ). 8353834 9 ) Reddy , B. , Maruyama , H. and Kelloff , G. Dose‐related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti‐inflammatory drug, during different stages of rat colon tumor development . Cancer Res. , 47 , 5340 – 5346 ( 1987 ). 3652039 10 ) Rao , C. , Rivenson , A. , Simi , B. , Zang , E. , Kelloff , G. , Steele , V. and Reddy , B. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti‐inflammatory agent . Cancer Res. , 55 , 1464 – 1472 ( 1995 ). 7882354 11 ) Marnett , L. J. Aspirin and the potential role of prostaglandins in colon cancer . Cancer Res. , 52 , 5575 – 5589 ( 1992 ). 1394181 12 ) Reddy , B. S. , Rao , C. V. and Seibert , K. Evaluation of cyclooxygenase‐2 inhibitor for potential chemopreventive properties in colon carcinogenesis . Cancer Res. , 56 , 4566 – 4569 ( 1996 ). 8840961 13 ) Takahashi , M. , Fukutake , M. , Yokota , S. , Ishida , K. , Wakabayashi , K. and Sugimura , T. Suppression of azoxymethane‐induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2 . J. Cancer Res. Clin. Oncol. , 122 , 219 – 222 ( 1996 ). 8601574 14 ) Yoshimi , N. , Kawabata , K. , Hara , A. , Matsunaga , K. , Yamada , Y. and Mori , H. Inhibitory effect of NS‐398, a selective cyclooxygenase‐2 inhibitor, on azoxymethane‐induced aberrant crypt foci in colon carcinogenesis of F344 rats . Jpn. J. Cancer Res. , 88 , 1044 – 1051 ( 1997 ). 9439679 15 ) Eberhart , C. E. , Coffey , R. J. , Radhika , A. , Giardiello , F. M. , Ferrenbach , S. and DuBois , R. N. Up‐regulation of cyclooxygenase‐2 gene expression in human colorectal adenomas and adenocarcinomas . Gastroenterology , 107 , 1183 – 1188 ( 1994 ). 7926468 16 ) Jones , D. A. , Carlton , D. P. , Mcintyre , T. M. , Zimmerman , G. A. and Prescott , S. M. Molecular cloning of human prostaglandin endoperoxide synthases type II and demonstration of expression in response to cytolines . J. Biol. Chem. , 268 , 9049 – 9054 ( 1993 ). 8473346 17 ) Seibert , K. , Zhang , Y. , Leahy , K. , Hauser , S. , Masferrer , J. , Perkins , W. , Lee , L. and Isakson , P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain . Proc. Natl. Acad. Sci. USA , 91 , 12013 – 12017 ( 1994 ). 7991575 18 ) Barnnett , J. , Chow , J. , Ives , D. , Chiou , M. , Mackenzie , R. , Osen , E. , Nguyen , B. , Tsing , S. , Bach , C. and Freire , J. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system . Biochim. Biophys. Acta , 1209 , 130 – 139 ( 1994 ). 7947975 19 ) Laneuvill , O. , Breuer , D. K. , Dewitt , D. L. , Hla , T. , Funk , C. D. and Smith , W. L. Differential inhibition of human prostaglandin endoperoxide H synthases‐1 and ‐2 by nonsteroidal anti‐inflammatory drugs . J. Pharmacol. Exp. Ther. , 271 , 927 – 934 ( 1994 ). 7965814 20 ) Griswold , D. E. and Adams , J. L. Constitutive cyclooxygenase (COX‐1) and inducible cyclooxygenase (COX‐2): rationale for selective inhibition and progress to date . Med. Res. Rev. , 16 , 181 – 206 ( 1996 ). 8656779 21 ) Spangler , R. S. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti‐inflammatory drug therapy . Semin. Arthritis Rheum. , 26 , 435 – 445 ( 1996 ). 8870111 22 ) Lee , P. P. and Ip , M. M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase . Prostaglandins Leukot. Essent. Fatty Acids , 45 , 21 – 31 ( 1992 ). 1546063 23 ) Rose , D. P. and Connoly , J. M. Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture . Cancer Res. , 50 , 7139 – 7144 ( 1990 ). 2224849 24 ) Kitagawa , H. and Noguchi , M. Comparative effects of piroxicam and esculetin on incidence, proliferation, and cell kinetics of mammary carcinomas induced by 7,12‐dimethylbenz[a]anthracene in rats on high‐ and low‐diets . Oncology , 51 , 401 – 410 ( 1994 ). 8052480 25 ) Thompson , H. J. and Meeker , L. D. Induction of mammary gland carcinomas by the subcutaneous injection of 1‐methyl‐1‐nitrosourea . Cancer Res. , 43 , 1628 – 1629 ( 1983 ). 6831409 26 ) Wood , G. S. and Warnke , R. Endogenous avidin‐binding activity in tissues and its relevance to biotin‐avidin detection systems . J. Histochem. Cytochem. , 29 , 1196 – 1204 ( 1981 ). 7028859 27 ) Broder , S. Perspectives on cancer in Japan and the United States . Jpn. J. Cancer Res. , 84 , 821 – 830 ( 1993 ). 8407543 28 ) Thompson , H. J. , Briggs , S. , Paranka , N. S. , Piazza , G. A. , Brendel , K. , Gross , P. H. , Sperl , G. J. , Pamukcu , R. and Ahnen , D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac . J. Natl. Cancer Inst. , 87 , 1259 – 1260 ( 1995 ). 7563174 29 ) McCormick , D. L. and Moon , R. C. Indomethacin inhibits mammary carcinogenesis in rats . Proc. Int. Assoc. Breast Cancer Res. , 1 , 43 ( 1983 ). 30 ) McCormick , D. L. and Moon , R. C. Inhibition of mammary carcinogenesis by flurbiprofen, a non‐steroidal antiin‐flammatory agent . Br. J. Cancer , 48 , 859 – 861 ( 1983 ). 6652027 31 ) Thompson , H. J. , Jiang , C. , Lu , J. , Mehta , R. G. , Piazza , G. A. , Paranka , N. S. , Pamukcu , R. and Ahnen , D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis . Cancer Res. , 57 , 267 – 271 ( 1997 ). 9000566 32 ) Hara , A. , Yoshimi , N. , Niwa , M. , Ino , N. and Mori , H. Apoptosis induced by NS‐398, a selective cyclooxygenase‐2 inhibitor, in human colorectal cancer cell lines . Jpn. J. Cancer Res. , 88 , 600 – 604 ( 1997 ). 9263538 33 ) Ohshima , H. and Bartsch , H. Chronic infections and inflammatory processes as cancer risk factors . Mutat. Res. , 305 , 253 – 264 ( 1994 ). 7510036 34 ) Lewis , J. G. and Adams , D. O. Inflammation, oxidative DNA damage, and carcinogenesis . Environ. Health Perspect. , 76 , 19 – 27 ( 1987 ). 3129286 35 ) Lewis , J. G. , Hamilton , T. and Adams , D. O. The effect of macrophage development on the release of reactive oxygen intermediates and lipid oxidation products, and their ability to induce oxidative DNA damage in mammalian cells . Carcinogenesis , 7 , 813 – 818 ( 1986 ). 3084120 36 ) Yoshimi , N. , Ino , N. , Suzui , M. , Tanaka , T. , Nakashima , S. , Nakamura , M. , Nozawa , Y. and Mori , H. The mRNA overexpression of inflammatory enzymes, phospholipase A 2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occurring carcinogen, 1‐hydroxyanthraquinone . Cancer Lett. , 97 , 75 – 82 ( 1995 ). 7585482 37 ) Yoshimi , N. , Sato , S. , Makita , H. , Wang , A. , Hirose , Y. , Tanaka , T. and Mori , H. Expression of cytokines, TNF‐alpha and IL‐1 alpha, in MAM acetate and 1‐hydroxyan‐thraquinone‐induced colon carcinogenesis of rats . Carcinogenesis , 15 , 783 – 785 ( 1994 ). 8149497 38 ) Oshima , M. , Dinchuk , J. E. , Kargman , S. L. , Oshima , H. , Hancock , B. , Kwong , E. , Trzaskos , J. M. , Evans , J. F. and Taketo , M. M. Suppression of intestinal polyposis in ApcΔ 716 knockout mice by inhibition of cyclooxygenase 2 (COX‐2) . Cell , 87 , 803 – 809 ( 1996 ). 8945508 39 ) Nakatsugi , S. , Fukutake , M. , Takahashi , M. , Fukuda , K. , Isoi , T. , Taniguchi , Y. , Sugimura , T. and Wakabayashi , K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase inhibitor, in Min mice . Jpn. J. Cancer Res. , 88 , 1117 – 1120 ( 1997 ). 9473726 40 ) Buckman , D. K. , Hubbard , N. E. and Erickson , K. L. Eicosanoids and linoleate‐enhanced growth of mouse mammary tumor cell . Prostaglandins Leukot. Essent. Fatty Acids , 44 , 177 – 184 ( 1991 ). 1667043 41 ) Blomgren , H. and Andersson , G. K. Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids . Anticancer Res. , 12 , 981 – 986 ( 1992 ). 1622156",
  "plain_text": "We investigated the modifying effects of nabumetone, a relatively selective cyclooxygenase‐2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N ‐methyl‐ N ‐nitrosourea(MNU)‐induced mammary carcinogenesis in female Sprague‐Dawley rats. A total of 124 rats, 6 weeks old, were divided into 6 groups. At 50 days of age, groups 1, 2, and 3 were treated with MNU (50 mg/kg body weight) by subcutaneous injection. From the age of 8 weeks, groups 2 and 4 were given 0.03% nabumetone in the diet and groups 3 and 5 were given 0.03% esculetin in the diet. All rats were necropsied at the termination (25 weeks after the start of experiment). The incidence and multiplicity of neoplasms in group 2 were significantly smaller than those in group 1 ( P <0.005 and P <0.001, respectively). The incidence of neoplasms in group 3 was also significantly smaller than that in group 1 ( P <0.05). These results indicate that the intake of nabumetone or esculetin during the time corresponding to the post initiation phase has a chemopreventive effect on MNU‐induced mammary carcinogenesis in rats."
}
